FDA Okays Weekly Option in Achondroplasia - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • By

  • Kathryn Wighton

  • March 2, 2026

  • 2 min

Share

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

  • by Kathryn Wighton

  • March 2, 2026

Related Content

Sedative medications: a potentially modifiable risk factor for improving neurocognitive outcomes after critical illness in infants and children

Association of serum growth differentiation factor 11 with asthma severity, inflammation, and airway remodeling in pediatric patients

Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor